Sara Morrow

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Steven M. Horwitz, Raphael Koch, Pierluigi Porcu et al. · Blood · 2017 · 283 citations · Full text

Medicine, Oncology, Pharmacology +7

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

Dennis Dobrovolsky, Eric S. Wang, Sara Morrow et al. · Blood · 2018 · 169 citations · Full text

Medicine, Cancer Biology, Oncology +13

Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer

Jaclyn Sceneay, Gregory J. Goreczny, Kristin Wilson et al. · Cancer Discovery · 2019 · 156 citations · Full text

Life Sciences, Immunology, Oncology +17

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Samuel Y. Ng, Noriaki Yoshida, Amanda L. Christie et al. · Nature Communications · 2018 · 114 citations · Full text

Medicine, Oncology, Pharmacology +12

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie et al. · Blood · 2018 · 63 citations · Full text

Medicine, Immunology, Oncology +16